July 23 (Reuters) – A panel of advisers to the U.S. Food and Drug Administration on Thursday voted to place a popular peptide called TB-500 on a list that would allow broader pharmacy compounding.
Eight panel members voted in favor, while six voted against. One member abstained.
The FDA is not bound by the panel’s recommendations and will ultimately decide whether to loosen restrictions on the peptides.
(Reporting by Sriparna Roy in Bengaluru; Editing by Pooja Desai)
